Rising prevalence of cardiovascular and inflammatory diseases, increasing application of CRP for diagnostic purposes, and extensive research activities on C-sensible protein are key factors driving market growth

The global C-sensible protein testing market size is expected to reach USD 1.93 Billion by 2028 and register a CAGR of 1.8% over the forecast period, according to the latest report by Reports and Data. Increasing incidence of cardiovascular and chronic inflammatory disease, rising adoption of C-sensible Protein (CRP) testing in primary care settings, and increasing application of CRP testing in diagnosis of inflammatory and infectious diseases are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing investment and funding to accelerate research on applications and importance of CRP are also expected to contribute to revenue growth of the market going ahead.

C-sensible protein is an acute phase protein which is primarily synthesized in liver in response to inflammation or infection. C-sensible protein test assesses the quantity of this protein in the blood to diagnose conditions or infections that cause inflammation in the body. CRP has been used for indication of infection and cardiovascular events for years, but currently ongoing research has hinted at its crucial role in inflammatory processes and host response to infection. High sensitivity assays are used to detect baseline levels of CRP and screen patients who are at-risk for developing any chronic inflammatory disease. CRP has been increasingly incorporated into routine clinical practice and this is expected to further drive market growth over the forecast period.

CRP also has various R&D applications, particularly to create potentially effective compounds for treating chronic inflammatory diseases. In addition, various initiatives to raise awareness about prevention and treatment of chronic disease is also expected to fuel revenue growth of the market over the forecast period. However, lack of awareness regarding CRP testing and inconclusive report of CRP testing is expected to restrain market growth to a certain extent over the forecast period.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC])@ https://www.reportsanddata.com/sample-enquiry-form/4051

The report puts an emphasis on the information regarding the key players with a special focus on their company profile, business overview, recent advancements, product catalog, and strategic business plans. It provides a comprehensive overview of the strategic alliances in the market under taken by the key players such as mergers and acquisitions, joint ventures, collaborations, partnerships, agreements, product launches, brand promotions, and corporate deals, among others.

Key companies operating in the market and profiled in the report include:

Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics Incorporated, Siemens, Abbott Laboratories, Laboratory Corporation of America Holdings, Merck KGaA, Abaxis, Inc., Ortho Clinical Diagnostics, Getein Biotech, Inc., HORIBA, Ltd., Randox Laboratories Ltd., Aidianm, and BODITECH MED INC.

Order This Report@ https://www.reportsanddata.com/report-pricing/4051

The C-Sensible Protein Testing market takes into account major geographical locations such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa to offer key insights into market growth, market size, market share, revenue growth, current and emerging trends, supply and demand ratio, import/export, consumer demand and behavior, and presence of key players in each region. The report offers an in-depth country wise analysis to impart better understanding of the market and its growth prospects.

Segments Covered in the report

Assay Type Outlook (Revenue, USD Billion; 2018-2028)

  • ELISA
  • Turbidometric
  • Immunoturbidometric

Application Outlook (Revenue, USD Billion; 2018-2028)

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

End-use Outlook (Revenue, USD Billion; 2018-2028)

  • Clinics
  • Hospitals
  • Diagnostic Labs

Key Regions Analyzed in the Report include:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Rest of MEA

Furthermore, it consists information about individual segment of the C-Sensible Protein Testing market based on the types and application. The report also offers insights about the key segments expected to register significant revenue growth over the forecast period and primary trends influencing their growth. It also offers CAGR and market share values for each segment to provide clear understanding of demand and trend in the global market.

Some Key Highlights From the Report:

  • Immunoturbidimetric assay segment is expected to account for largest revenue share during the forecast period attributable to rapid development and availability of cost-effective automated and sensitive assays.
  • Cardiovascular disease segment is expected to register robust revenue growth over the forecast period owing to increasing global prevalence of cardiovascular conditions, growing demand for quick diagnostic methods, rising need for early detection, and large number of C-sensible protein tests performed for diagnosis of CVD.
  • Clinics segment is expected to register considerable revenue growth between 2021 and 2028 owing to increasing adoption of POC CRP testing in primary care settings, cost-effectiveness, and need for rapid and accurate results.
  • North America is expected to account for largest revenue share over the forecast period attributable to increasing incidence of CVD, rheumatoid arthritis, and other inflammatory conditions, presence of well-established healthcare infrastructure, and favorable reimbursement scenario.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4051

Thank you for reading our report. For any specific details on customization of this report, please get in touch with us. We will ensure the report you get is well-suited to your needs.

Explore More Industry Research by Reports and Data:

In-Vitro Diagnostics (IVD) Quality Control Market @ https://www.biospace.com/article/in-vitro-diagnostics-ivd-quality-control-market-growth-2022-2028-multiple-level-quality-control-analysis-and-identification-of-critical-analytical-system-issues/

Taxifolin Market @ https://www.biospace.com/article/taxifolin-market-demand-2022-2028-rising-awareness-regarding-health-and-fitness-among-people-globally/

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com